3 EU Biotechs which Over-performed in 2015

30/12/2015 - 2 minutes

2015 was a crazy year for the Biotech industry, probably the craziest since the birth of the industry 40 years ago. I looked back on this year and here’s my personal top 3 of EU Biotechs which over-performed. I sorted them out in top partnerships, clinical trials and fundraising.

(Of course, this lists is not exhaustive and is not aimed to be so)

 

Top Partnerships – M&A deals

Galapagos + Gilead – Abbvie

Galapagos is a billion-euro Biotech from Belgium which had a big partnership with Abbvie. The american Biotech decided not to exercise its options, leaving Galapagos no other choice than finding a new partner. And just before the end of year, Galapagos announced it signed a €2Bn deal with Gilead, the extremely successful Californian Biotech. That’s massive!

Related Content

Bonus video: Exclusive Interview of Galapagos’ SVP Business Development

 

Top Clinical Trials Results

Cellectis’ Miracle Saving of a 11-month Baby Girl

CAR-T was the big deal of 2015.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!

You might also be interested in the following: